Trachoma Clinical Trial
Official title:
Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study
The investigators aim to evaluate a new potentially cost-effective approach to improving trichiasis surgery outcomes, perioperative topical anti-inflammatory therapy. The investigators hypothesize that adjunctive topical fluorometholone therapy following trichiasis surgery will reduce the risk of recurrent trichiasis. The rationale for this hypothesis is that interruption of inflammation postoperatively would reduce postoperative scarring, leading to better outcomes. As an initial step toward evaluating this modality, the investigators believe it to be necessary to evaluate topical corticosteroid therapy in a safety-oriented study, for which the investigators also hypothesize that fluorometholone will have a perioperative safety profile acceptable for large-scale programmatic use. Topical corticosteroid therapy is associated with potential risks of cataract induction and intraocular pressure (IOP) elevation in susceptible individuals. Fluorometholone has lower intraocular penetration than alternative corticosteroids, with correspondingly less IOP-raising effect while still having favorable effects on conjunctival inflammation, and is a low-cost generic drug. Its poor delivery of corticosteroid into the eye itself provides an advantage in this setting, as the major side effects of therapy are the result of intraocular effects, and therapy only is needed to the conjunctiva. However, prior to use in a large-scale trial it is sensible to make sure adverse outcomes are not observed in a substantial number of TT patients in a smaller scale trial. Secondary goals of such a trial are to evaluate alternative topical corticosteroid dosing schedules to identify an optimal dosing schedule and to identify any preliminary signals of potential efficacy.
Protocol Title: Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation
Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study
Study Design: Randomized, double-masked, dose-ranging study of three dose levels of
fluorometholone 0.1% or placebo in one eye of subjects with trachomatous trichiasis (TT)
undergoing lid rotation surgery
Primary Study Objective: Evaluate the safety and tolerability of three (3) doses of
fluorometholone 0.1% in subjects with trachomatous trichiasis (TT) undergoing lid rotation
surgery (Bilamellar Tarsal Rotation)
Secondary Study Objective: Conduct a preliminary assessment of the efficacy of three (3)
doses of fluorometholone 0.1% in subjects with trachomatous trichiasis (TT) undergoing lid
rotation surgery (Bilamellar Tarsal Rotation)
Number of Subjects: Up to 156 eyes of up to 156 subjects
Study Population: Subjects with trachomatous trichiasis (TT) undergoing lid rotation surgery
(Bilamellar Tarsal Rotation)
Test Articles:
1. Fluorometholone 0.1% one drop twice daily for four weeks
2. Placebo one drop twice daily for four weeks
3. Fluorometholone 0.1% one drop four times daily for four weeks
4. Placebo one drop four times daily for four weeks
5. Fluorometholone 0.1% one drop four times daily for eight weeks
6. Placebo one drop four times daily for eight weeks
Visit Schedule: Following trichiasis surgery on Day 0, subjects will return for study visits
approximately on Days 14, 28, 56, 90, and 365
Tolerability Parameters:
- Treatment-emergent ocular symptoms/signs
- Discontinuation of drug / treatment because of side effects
Safety Parameters:
- Intraocular pressure elevation ≥30 mm Hg
- Cataract
- Adverse events
- Treatment emergent abnormal ophthalmic findings
- Treatment emergent external examination findings
- Visual acuity
Efficacy Parameters:
- Trichiasis recurrence
- Entropion recurrence
- Trachoma activity grade (to the extent activity can be graded in eyes with severe
trachomatous scarring)
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03676140 -
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 3 | |
Completed |
NCT01202331 -
Tripartite International Research for the Elimination of Trachoma
|
Phase 4 | |
Completed |
NCT05634759 -
Enhancing the A in SAFE for Trachoma
|
Phase 4 | |
Recruiting |
NCT04185402 -
Azithromycin Reduction to Reach Elimination of Trachoma
|
Phase 4 | |
Active, not recruiting |
NCT00886015 -
Modified Instrumentation for Surgery to Correct Trichiasis
|
Phase 3 | |
Completed |
NCT00792922 -
Partnership for Rapid Elimination of Trachoma
|
Phase 4 | |
Completed |
NCT00522860 -
A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery
|
Phase 4 | |
Completed |
NCT00221364 -
Trachoma Elimination Follow-up
|
Phase 4 | |
Completed |
NCT00322972 -
Trachoma Amelioration in Northern Amhara (TANA)
|
Phase 4 | |
Withdrawn |
NCT00286026 -
Azithromycin in Control of Trachoma II
|
Phase 4 | |
Completed |
NCT00347763 -
Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
|
Phase 4 | |
Terminated |
NCT04002726 -
App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders
|
N/A | |
Terminated |
NCT03997487 -
Smartphone App for Taking Images of Conjunctivae
|
N/A | |
Not yet recruiting |
NCT06289647 -
Azithromycin Reduction to Reach Elimination of Trachoma B
|
Phase 4 | |
Withdrawn |
NCT02655432 -
Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population
|
Phase 0 | |
Completed |
NCT01767506 -
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
|
N/A | |
Completed |
NCT00618449 -
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
|
Phase 4 | |
Completed |
NCT00356720 -
Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma
|
Phase 3 | |
Completed |
NCT03813069 -
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
|
Phase 2 | |
Recruiting |
NCT03335072 -
Kebele Elimination of Trachoma for Ocular Health
|
Phase 4 |